The impact and value of structure-based drug design to pharmaceutical discovery across the industry are now undeniable, with many break-through therapies on the market that are structure based in nature. Enabling the structural research is the Industrial Macromolecular Crystallography Association-Collaborative Access Team (IMCA-CAT), formed over 25 years ago as a world-class research facility at the synchrotron at Argonne National Laboratory. What makes IMCA-CAT unique is the strategy of the founding consortium to comprehensively provide for the evolving needs of industry in one facility. This includes year-round high-quality data, capabilities that match target portfolios, throughput and capacity that are never limiting, and unfailing security. Here, we illuminate the unique capabilities offered by IMCA-CAT and instruct how all industrial organizations can access this facility.

现在，不可否认的是，基于结构的药物设计对整个行业中的药物发现的影响和价值是不可否认的，市场上有许多突破性疗法都是基于结构的。进行结构研究的是工业大分子晶体学协会协作访问团队（IMCA-CAT），该团队成立于25年前，是阿贡国家实验室同步加速器的世界级研究机构。IMCA-CAT的与众不同之处在于，成立联合体的策略是在一个机构中全面满足行业不断发展的需求。这包括全年的高质量数据，与目标产品组合相匹配的功能，永不限制的吞吐量和容量以及安全性。这里，